• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Journey Medical Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    6/24/25 8:30:42 AM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DERM alert in real time by email
    false 0001867066 0001867066 2025-06-24 2025-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 24, 2025

     

    Journey Medical Corporation

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware  001-41063  47-1879539
    (State or Other Jurisdiction
    of Incorporation)
      (Commission File Number)  (I.R.S. Employer
    Identification No.)

     

    9237 E Via de Ventura Blvd., Suite 105

    Scottsdale, AZ 8525

    (Address of principal executive offices)

     

    Registrant’s telephone number, including area code: (480) 434-6670

     

    Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
      
    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
      
    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
      
    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class Trading Symbol(s) Name of each exchange
    on which registered
    Common Stock DERM The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company   x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 8.01 Other Events.

     

    On June 24, 2025, Journey Medical Corporation (“Journey Medical” or the “Company”) announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025. A copy of the press release issued by Journey Medical is attached hereto as Exhibit 99.1 and incorporated herein by reference.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    The following exhibits are furnished herewith:

     

    Exhibit
    Number
      Description
    99.1   Press release issued by Journey Medical Corporation, dated June 24, 2025
    104   Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Journey Medical Corporation
      (Registrant)
       
      By: /s/ Claude Maraoui
        Claude Maraoui
        Chief Executive Officer, President and Director

     

    Date: June 24, 2025

     

     

     

    Get the next $DERM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DERM

    DatePrice TargetRatingAnalyst
    8/22/2024$9.00Buy
    Rodman & Renshaw
    6/28/2024$11.00Buy
    ROTH MKM
    2/25/2022$9.00Overweight
    Cantor Fitzgerald
    12/16/2021$15.00Buy
    Roth Capital
    12/7/2021$14.00Buy
    B. Riley Securities
    More analyst ratings

    $DERM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Journey Medical with a new price target

      Rodman & Renshaw initiated coverage of Journey Medical with a rating of Buy and set a new price target of $9.00

      8/22/24 7:21:37 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM resumed coverage on Journey Medical with a new price target

      ROTH MKM resumed coverage of Journey Medical with a rating of Buy and set a new price target of $11.00

      6/28/24 7:38:15 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Journey Medical with a new price target

      Cantor Fitzgerald initiated coverage of Journey Medical with a rating of Overweight and set a new price target of $9.00

      2/25/22 9:05:17 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    SEC Filings

    See more
    • Journey Medical Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Journey Medical Corp (0001867066) (Filer)

      6/26/25 4:05:53 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Journey Medical Corp (0001867066) (Filer)

      6/24/25 8:30:42 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Journey Medical Corporation

      SCHEDULE 13G/A - Journey Medical Corp (0001867066) (Subject)

      5/15/25 4:15:24 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    Leadership Updates

    Live Leadership Updates

    See more
    • Journey Medical to Join Russell 2000® and Russell 3000® Indexes

      SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution. "We are very pleased to be included in the Russell 2000® and Russell 3000

      6/24/25 8:30:29 AM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

      SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

      4/1/25 4:01:16 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

      SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that on July 9, 2024, it appointed Michael C. Pearce to its Board of Directors. Mr. Pearce is a principal investor with an emphasis on healthcare. Since 2015, he has served as an advisor to EP Group and board member of its predecessor parent company, Evening Post Industries ("EPI"). At EPI, he served on the audit, compensation, and inves

      7/11/24 4:05:39 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    Financials

    Live finance-specific insights

    See more
    • Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., May 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Admin

      5/14/25 4:01:35 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

      SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2025 financial results after the U.S. financial markets close on Wednesday, May 14, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, May 14, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. s

      5/7/25 4:01:25 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

      FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended December 31, 2024 were $56.1 million Met All Financial Guidance for 2024 Emrosi Phase 3 Clinical Trial Results Published in JAMA Dermatology Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., March 26, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approve

      3/26/25 4:01:00 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Rosenwald Lindsay A Md bought $30,400 worth of shares (10,000 units at $3.04), increasing direct ownership by 7% to 144,245 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      3/27/24 7:00:16 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maraoui Claude bought $34,790 worth of shares (10,000 units at $3.48), increasing direct ownership by 0.46% to 2,163,430 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      3/25/24 4:03:29 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Smith Justin Adam bought $104,100 worth of shares (30,000 units at $3.47), increasing direct ownership by 29% to 134,717 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      3/25/24 4:02:02 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Alloush Ramsey was granted 46,863 shares, increasing direct ownership by 9% to 551,680 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      6/20/25 4:06:47 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Benesch Joseph was granted 28,907 shares, increasing direct ownership by 14% to 232,464 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      6/20/25 4:06:01 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Maraoui Claude was granted 49,277 shares, increasing direct ownership by 2% to 2,397,590 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      6/20/25 4:05:13 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Journey Medical to Join Russell 2000® and Russell 3000® Indexes

      SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution. "We are very pleased to be included in the Russell 2000® and Russell 3000

      6/24/25 8:30:29 AM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

      SCOTTSDALE, Ariz., June 20, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that a data analysis from two Phase 3 multicenter clinical trials, evaluating Emrosi™ for the treatment of moderate-to-severe papulopustular rosacea in adults will be presented at the Society of Dermatology Physician Associates (SDPA) 2025 Summer Dermatology Conference taking place June 25-29 in Washington

      6/20/25 8:30:33 AM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Announces Emrosi™ Featured on "The Balancing Act" Airing on Lifetime TV

      National TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET SCOTTSDALE, Ariz., June 09, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that a new segment of "The Balancing Act®" airing on Lifetime TV and sponsored by the Company featured Emrosi™ (40 mg Minocycline Hydroch

      6/9/25 8:30:01 AM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Journey Medical Corporation

      SC 13G - Journey Medical Corp (0001867066) (Subject)

      11/29/24 2:00:25 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Journey Medical Corporation (Amendment)

      SC 13G/A - Journey Medical Corp (0001867066) (Subject)

      12/29/22 5:15:07 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Journey Medical Corporation

      SC 13G - Journey Medical Corp (0001867066) (Subject)

      8/17/22 4:01:13 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care